Sector · Forward funding
Life sciences forward funding
Life sciences forward funding lets an investor fund construction of a laboratory building and hold a pre-let, lab-enabled asset at completion. This page covers lab-enabled shells versus fitted CAT A and CAT B labs, Golden Triangle clusters, biotech to pharma covenants and indicative pricing as at Q2 2026.
Life sciences forward funding is a structure in which an institutional investor acquires a site or shell, funds the cost of building a laboratory building in staged drawdowns, and holds the completed, lab-enabled asset against a pre-let to a biotech, pharmaceutical or research occupier. The investor takes construction and delivery risk during the build in exchange for a development margin embedded in the yield, and receives income once the specialist building is handed over and occupied. This sits between a standing investment purchase and speculative development, and it has become a core application of forward funding as laboratory real estate has moved into the institutional mainstream. The active UK developer and investor set includes British Land, Stanhope, Kadans Science Partner (owned by AXA IM Alts), Bruntwood SciTech, Oxford Properties, BioMed Realty (owned by Blackstone), Reef Group and Tishman Speyer, alongside the universities, research charities and pharmaceutical groups that anchor much of the demand.
Laboratory buildings are not offices with a noun swapped in. They carry structural, ventilation, power and vibration requirements that a standard commercial building cannot meet without wholesale reconstruction, and their value turns on cluster location and occupier covenant to a degree that has no parallel in general commercial property. Understanding what makes a laboratory fundable, and how the specialist capex is split between investor and occupier, is the substance of the sector.
Definition and life sciences market context
Life sciences real estate converts serviced, high-specification space into laboratory capacity for research and manufacturing occupiers. Demand is driven by venture-funded biotech, scaling therapeutics and diagnostics companies, large pharmaceutical groups, universities and research charities, and it concentrates geographically in the Golden Triangle formed by Oxford, Cambridge and London. Within London, King’s Cross, White City, Canary Wharf, London Bridge and the Stevenage cluster have emerged as purpose-built laboratory locations, and named developers and platforms including British Land, Stanhope, Kadans Science Partner, Bruntwood SciTech, Oxford Properties, BioMed Realty, Reef Group and Tishman Speyer have live and consented schemes across these clusters. The binding scarcity is not capital but deliverable, correctly specified space in the right cluster, close to the research institutions and talent that occupiers need.
Cluster gravity, not raw site availability, sets both feasibility and value. A laboratory building draws its occupiers from a catchment defined by proximity to universities, teaching hospitals, spinout pipelines and existing occupier ecosystems, and space more than a short commute from that catchment carries materially higher letting risk. Against a backdrop of structural demand growth from the therapeutics and diagnostics sectors, and a shortage of Grade A laboratory stock in the strongest clusters, forward funding gives capital a route into new-build laboratory stock at scale that the standing market cannot readily supply.
Why investors forward fund life sciences
Investors forward fund life sciences to secure income from a supply-constrained, structurally growing sector that the standing market rarely offers at scale. A completed laboratory building pre-let to a strong occupier typically carries a lease of 10 to 15 years, frequently with fixed or index-linked uplifts, producing a durable income stream underpinned by high tenant fit-out investment and sticky, cluster-dependent occupiers. Laboratory tenants sink substantial capital into their fit-out, benches, fume cupboards and specialist services, which raises switching costs and supports lease renewal, and this occupier stickiness is a defining feature of the investment case.
The covenant, and its variability, sits at the centre of the analysis. Life sciences occupiers span a wide credit spectrum, from venture-backed biotech at the weakest and most cash-runway dependent end, through scaled and listed companies, to large pharmaceutical groups and research institutions at the strongest end. A pre-let to a global pharma group, a university or a research charity underwrites a forward funding far more readily than a lease to an early-stage, pre-revenue biotech, and the covenant strength drives both the fundability and the price. The trade-off is that laboratory buildings carry risks an office does not: the specialist capex is expensive and partly tenant-specific, obsolescence in ventilation and services must be managed, and a weak covenant can leave a landlord holding a highly specified building through a re-letting. The forward funding return compensates for taking construction and letting risk ahead of stabilised income, and disciplined investors price the covenant spectrum explicitly rather than treating all life sciences demand as equal.
Correctly specified space inside a proven cluster, not capital, is the binding constraint on a fundable laboratory, and covenant quality ranges from venture-backed biotech to global pharma across the same asset class.
Structure variants
Life sciences forward funding divides principally by how much of the specialist laboratory fit-out the investor funds. In a lab-enabled shell deal the investor funds the base build and the enabling infrastructure, the structure, ventilation provision, power, risers and plant, while the occupier installs the CAT A base laboratory infrastructure and the CAT B occupier-specific fit-out as a separate capex programme. In a fitted deal the investor funds CAT A laboratory infrastructure, and sometimes contributes to CAT B, receiving a higher rent and yield to reflect the additional capex and the greater obsolescence exposure carried on the balance sheet. The third axis is the covenant that anchors the pre-let, which ranges from research institution and pharma at the strong end to venture-backed biotech at the weaker end and drives the price more than any single specification point.
Occupier profile also shapes the structure. A single pre-let to a strong covenant produces the clean income that forward funding is built around, whereas a multi-let building aimed at scaling biotech occupiers behaves more like an operating ecosystem, with shorter leases, incubator or grow-on space and more management intensity. Choosing between a fully de-risked pre-let and a partly speculative delivery is closely related to the wider question of pre-let structures and the mechanics of forward funding versus forward purchase.
| Structure variant | Investor funds | Occupier funds | Yield and risk profile |
|---|---|---|---|
| Lab-enabled shell, pre-let | Base build, ventilation, power, risers, plant | CAT A and CAT B laboratory fit-out | Lower base cost, keener yield, less specialist obsolescence held by investor |
| Fitted CAT A / CAT B, pre-let | Base build plus CAT A, sometimes part CAT B | Residual CAT B and equipment | Higher rent and yield, more capex and obsolescence risk to investor |
| Speculative / multi-let biotech | Base build and often CAT A across floors | CAT B per occupier | Letting risk, granular covenant, incubator management intensity |
What investors require
Investors require a correctly specified, cluster-located building let to a covenant they can underwrite before they will commit funding to a laboratory. The primary due diligence gate is specification: a laboratory building must meet structural, servicing and environmental thresholds that cannot be retrofitted into a standard office without wholesale reconstruction, and these are tested at heads of terms rather than resolved later. Location follows directly, because an asset inside a proven cluster carries far lower letting and liquidity risk than an equivalent building outside it. Beyond spec and cluster, the requirements are covenant, scale and environmental credentials.
- Laboratory specification. Slab-to-slab height typically around 4.0 to 4.5 metres to allow a serviced lab floor, floor loading commonly 6 to 10 kilonewtons per square metre, high fresh-air ventilation with fume cupboard and once-through air capacity, elevated power provision, generous riser and plant space, goods lifts, and controlled vibration criteria for sensitive equipment.
- Cluster location. A site within the Golden Triangle or a proven London laboratory location, close to universities, teaching hospitals, talent and existing occupier ecosystems.
- Covenant. Financial strength of the occupier along the biotech to pharma spectrum, guarantees, rent cover, and the depth of demand for the space if the tenant fails.
- Scale and flexibility. A building of institutional scale, typically £40m to £200m GDV, with floorplates that suit both single and multiple occupiers and the ability to subdivide.
- ESG and EPC. A strong EPC rating, low embodied and operational carbon despite the energy intensity of laboratory ventilation, and heat recovery, which increasingly affect both lettability and pricing.
- Fit-out split. A clear allocation of CAT A and CAT B scope, any landlord contribution, and reinstatement obligations, defined in the funding agreement and agreement for lease.
The energy intensity of laboratory ventilation makes ESG unusually material in this sector. High air change rates and once-through air drive operational energy well above a standard office, so heat recovery, efficient plant and renewable procurement matter to both the occupier’s operating cost and the investor’s exit, and this is diligenced alongside the base specification rather than as an afterthought.
Indicative pricing dynamics
Life sciences pricing turns on covenant, cluster and the fit-out basis. As at Q2 2026, indicative net initial yields for a prime, lab-enabled building pre-let to a strong covenant sit around 5.00% to 6.00%, with fitted CAT B labs on long institutional leases pricing keener and speculative, multi-let biotech space pricing wider to reflect letting and covenant risk. A lab-enabled shell prices differently from a fully fitted lab on a like-for-like covenant basis because the split of specialist capex and obsolescence risk differs, while the developer return reflects the construction and letting risk taken through the build. The figures below are indicative and move with the swap curve, so they should be re-tested at the point of any live transaction.
| Profile | Indicative net initial yield (as at Q2 2026) | Notes |
|---|---|---|
| Fitted CAT B, pharma or institution pre-let, strong covenant | 5.00% to 5.50% | Long lease, keenest pricing, most capex held by investor |
| Prime lab-enabled shell, pre-let, strong covenant | 5.50% to 6.00% | Investor funds shell and enabling infrastructure; occupier funds fit-out |
| Speculative / multi-let biotech, granular covenant | 6.25% to 7.50%+ | Letting risk, incubator and grow-on space, management intensity |
| Developer return on cost (forward funded build) | Priced as a margin over yield on cost | Reflects construction and letting risk |
The cluster premium is a defining feature of the pricing. A correctly specified building inside Oxford, Cambridge or a proven London cluster commands a materially keener yield and far deeper liquidity than an equivalent building outside those catchments, because occupier demand and talent do not travel. Covenant then modulates the price within a cluster, and a pre-let to a global pharma group or a research institution can sit a full point or more inside the yield attached to comparable space let to an early-stage biotech.
Worked example
Consider Panel Investor A, a specialist life sciences platform forward funding a lab-enabled building in an established Cambridge cluster. The figures are indicative and illustrative only, and do not represent an actual transaction.
| Metric | Indicative figure |
|---|---|
| Scale | c. 120,000 sq ft of lab-enabled and office space over multiple floors |
| Structure | Lab-enabled shell forward funding, investor funds shell and enabling infrastructure, occupier funds CAT A and CAT B fit-out |
| Gross development value | c. £110m GDV |
| Pre-let | 12 year lease to a scaled, listed life sciences covenant, index-linked uplifts, one break at year 10 |
| WALT at completion | c. 12 years to expiry, c. 10 years to first break |
| Rent | Contracted at heads of terms, structured to deliver the target yield on cost |
| Drawdown | Staged against construction milestones and pre-let conditions |
| Developer return | Margin on cost for delivering the building and putting the pre-let in place |
| Net initial yield at completion | c. 5.75% net initial (indicative, as at Q2 2026) |
In this illustration Panel Investor A acquires the site with the pre-let agreed, funds the base build and the enabling laboratory infrastructure through staged drawdowns tied to construction milestones, and takes handover of a let, lab-enabled asset on practical completion. The occupier funds and installs the CAT A and CAT B laboratory fit-out, benches, fume cupboards and specialist services. The developer earns a margin for delivering the building and putting the pre-let in place, and the investor holds income at a yield that reflects the lab-enabled shell risk profile rather than a fully fitted asset. The staged drawdown structure means capital is deployed against verified progress rather than in advance, which is a defining feature of golden brick and milestone-based funding disciplines applied to a laboratory programme, and it protects the developer return as a reward for delivery rather than a speculative uplift.
Process and timeline specifics
Life sciences forward funding timelines are governed by specification design and pre-let negotiation more than by planning alone. Fixing the laboratory specification, the slab-to-slab heights, ventilation strategy, power and riser provision and the CAT A and CAT B split, is a substantial pre-commitment exercise, because these provisions are expensive to change once construction begins and because the occupier’s technical requirements must be reconciled with the base-build design. Investors therefore diligence the specification, cluster position, covenant and pre-let terms before signing, and structure completion around a building that will let and hold value.
From heads of terms, the path runs through due diligence on specification, planning, covenant and the agreement for lease, to a funding agreement and building contract, then a construction period with staged drawdowns, and finally practical completion, occupier fit-out and rent commencement. The occupier’s CAT A and CAT B fit-out often runs after the base-build handover, so the funding agreement must be explicit about the boundary between landlord and tenant scope, any landlord contribution, and the point at which rent commences. Because the asset is weighed against alternatives such as data centre forward funding for its covenant and income length, and against office forward funding for its cluster dynamics and higher specification, investors compare the laboratory’s supply-constrained demand and occupier stickiness against its narrower tenant pool and specialist capex. To discuss a specific life sciences forward funding opportunity, get in touch.
Questions
Frequently asked questions
What is life sciences forward funding?
Life sciences forward funding is a structure in which an investor acquires a site or asset and funds the cost of building a laboratory building in staged drawdowns, then holds the completed, lab-enabled asset as a let investment. The developer delivers the base build and, in fitted deals, part of the specialist mechanical and electrical fit-out against a pre-let or agreement for lease. It differs from a forward purchase, where the investor pays only on practical completion and takes no construction funding risk.
What does lab-enabled mean and how does it differ from a fitted lab?
A lab-enabled shell is a building designed and serviced so that wet laboratory use is possible, with the structural, ventilation, power, riser and plant provisions in place, but without the fitted benches, fume cupboards and specialist services installed. A fitted lab adds CAT A base laboratory infrastructure, and CAT B adds the occupier-specific fit-out. Lab-enabled shells carry lower base-build cost and a keener net initial yield than a fully fitted CAT B lab, because the investor holds less specialist capex and less obsolescence risk.
Where do UK life sciences forward funding deals concentrate?
Deals concentrate in the Golden Triangle formed by Oxford, Cambridge and London, where research institutions, venture capital and occupier demand cluster most deeply. Within London, King's Cross, White City, Canary Wharf, London Bridge and Stevenage have emerged as purpose-built laboratory locations. Cluster proximity to universities, teaching hospitals and talent pools is the primary letting and liquidity driver, and sites outside established clusters carry materially higher letting risk.
What specification do life sciences investors require?
Investors require a slab-to-slab height that allows a serviced lab floor, typically around 4.0 to 4.5 metres, floor loading commonly in the range of 6 to 10 kilonewtons per square metre, high fresh-air ventilation with fume cupboard and once-through air capacity, elevated power provision, generous riser and plant space, goods lifts and controlled vibration criteria. These provisions distinguish a fundable lab building from a converted office and cannot be retrofitted cheaply, which is why specification is diligenced at heads of terms.
How does covenant strength vary across life sciences occupiers?
Covenant ranges from venture-backed biotech, which is the weakest and most cash-runway dependent, through scaled and listed life sciences companies, to large pharmaceutical groups and research institutions at the strongest end. A pre-let to a global pharma company, university or research charity underwrites a forward funding far more readily than a lease to an early-stage, pre-revenue biotech. Investors weigh the covenant against lease length, guarantees, rent cover and the depth of demand for the space if the tenant fails.
What yields do UK life sciences buildings trade at?
As at Q2 2026, indicative net initial yields for a prime, lab-enabled building pre-let to a strong covenant sit around 5.00% to 6.00%, with fitted CAT B labs on long institutional leases pricing keener and speculative, multi-let biotech space pricing wider to reflect letting and covenant risk. All figures are indicative and move with the swap curve, covenant and cluster. Pricing should be re-tested at the point of any live transaction.
Why do investors fund speculative laboratory space at all?
Investors fund a proportion of speculative or lab-enabled space because occupier demand in the strongest clusters can outrun ready supply, and biotech occupiers frequently need space faster than a bespoke pre-let programme allows. Speculative delivery in Oxford, Cambridge or a proven London cluster can capture rental growth and letting momentum, but it carries letting risk that a pre-let does not. Most forward funding still anchors on a pre-let or substantial pre-let, with speculative space priced at a wider yield.
Who funds the specialist fit-out in a life sciences forward funding?
It depends on the structure. In a lab-enabled shell deal the investor funds the base build and enabling infrastructure, and the occupier funds the CAT A and CAT B laboratory fit-out, benches, fume cupboards and specialist services. In a fitted deal the investor funds CAT A base laboratory infrastructure and prices a higher rent and yield to reflect the additional capex and obsolescence. The split, and any landlord fit-out contribution, is defined in the funding agreement and agreement for lease.